Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Measles as a potential oncolytic virus.

Adele K Fielding1

  • 1Department of Haematology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK. a.fielding@rfc.ucl.ac.uk

Reviews in Medical Virology
|November 17, 2004
PubMed
Summary

Measles virus (MV) shows promise as an oncolytic agent, effectively targeting cancer cells while sparing normal ones. Pre-clinical studies highlight its potential for genetic engineering to improve cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What next after the first BITE of the CD19 cherry in ALL?

Blood·2026
Same author

JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.

Leukemia·2026
Same author

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.

Blood·2024
Same author

Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts.

Blood advances·2024
Same author

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia.

HemaSphere·2024
Same author

Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.

American journal of hematology·2024

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Replicating viruses are increasingly explored for cancer therapy.
  • Measles virus (MV), particularly an attenuated vaccine strain, exhibits oncolytic potential.
  • MV demonstrates selective lysis of cancer cells with limited replication in normal cells, alongside stability and a favorable safety profile.

Purpose of the Study:

  • To review pre-clinical studies on the oncolytic efficacy of measles virus (MV).
  • To highlight advancements in MV engineering for enhanced cancer therapeutics.
  • To discuss challenges and future directions in MV-based cancer therapy.

Main Methods:

  • Review of pre-clinical research on measles virus (MV) as an oncolytic agent.
  • Analysis of genetic engineering strategies for recombinant MVs.
  • Evaluation of MV's safety and efficacy in cancer models.

Main Results:

  • Pre-clinical studies indicate significant oncolytic efficacy of MV against cancer cells.
  • MV exhibits selective replication and lysis in transformed cells.
  • Genetic modifications are being explored to enhance MV's therapeutic attributes and target specificity.

Conclusions:

  • Measles virus (MV) is a promising candidate for oncolytic virotherapy.
  • Ongoing research focuses on engineering MV for improved cancer targeting and therapeutic outcomes.
  • Further investigation into factors like anti-MV immunity is crucial for clinical translation.

Related Experiment Videos